PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 112 filers reported holding PHATHOM PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.31 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $352,601 | -23.7% | 34,002 | +5.3% | 0.00% | – |
| Q2 2023 | $462,308 | +1552.6% | 32,276 | +723.8% | 0.00% | – |
| Q1 2023 | $27,975 | -66.4% | 3,918 | -47.2% | 0.00% | – |
| Q4 2022 | $83,264 | +1.5% | 7,421 | 0.0% | 0.00% | – |
| Q3 2022 | $82,000 | +51.9% | 7,421 | +17.3% | 0.00% | – |
| Q2 2022 | $54,000 | -25.0% | 6,328 | +20.1% | 0.00% | – |
| Q1 2022 | $72,000 | -29.4% | 5,267 | +1.7% | 0.00% | – |
| Q4 2021 | $102,000 | -38.9% | 5,178 | 0.0% | 0.00% | – |
| Q3 2021 | $167,000 | +103.7% | 5,178 | +112.3% | 0.00% | – |
| Q2 2021 | $82,000 | +41.4% | 2,439 | +57.3% | 0.00% | – |
| Q1 2021 | $58,000 | +7.4% | 1,551 | -4.4% | 0.00% | – |
| Q4 2020 | $54,000 | +10.2% | 1,623 | +22.7% | 0.00% | – |
| Q3 2020 | $49,000 | -18.3% | 1,323 | -27.0% | 0.00% | – |
| Q2 2020 | $60,000 | +42.9% | 1,812 | +12.1% | 0.00% | – |
| Q1 2020 | $42,000 | -36.4% | 1,616 | -23.7% | 0.00% | – |
| Q4 2019 | $66,000 | – | 2,117 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 3,760,869 | $39,000,212 | 12.45% |
| Frazier Life Sciences Management, L.P. | 10,109,279 | $104,833,223 | 6.96% |
| Decheng Capital Management III (Cayman), LLC | 850,000 | $8,814,500 | 2.94% |
| Carlyle Group Inc. | 3,496,808 | $36,191,963 | 1.57% |
| Ghost Tree Capital, LLC | 395,000 | $4,096,150 | 1.35% |
| Newtyn Management, LLC | 500,000 | $5,185,000 | 1.28% |
| Altium Capital Management LP | 220,000 | $2,281,400 | 1.19% |
| StepStone Group LP | 422,085 | $4,377,021 | 0.98% |
| MPM BioImpact LLC | 347,332 | $3,601,833 | 0.96% |
| NEA Management Company, LLC | 1,276,595 | $12,238,290 | 0.94% |